Zentalis Pharmaceuticals grants 14,000 stock options to new employee under incentive award plan.

From “GlobeNewswire”: 2025-05-01 17:00:00

Zentalis Pharmaceuticals granted 14,000 stock options to a newly hired employee on May 1, 2025, under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $1.45 per share, with a 10-year term and vesting over four years. Vesting is contingent on continued service to the company. Zentalis is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer patients, with promising anti-tumor activity shown in clinical trials. For more information, visit www.zentalis.com or follow Zentalis on Twitter and LinkedIn. Contact Haibo Wang or Ron Moldaver for investor relations inquiries at [email protected].



Read more at “GlobeNewswire”: Zentalis Pharmaceuticals Announces Inducement Grant Under